Talk:Exenatide
Discussion page·3 threads·no archives
This is the discussion page for the article Exenatide. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.
Class-effect cautionResolved
The EXSCEL result is the clearest single argument against treating cardiovascular benefit as a class property, and this article is the natural place to say so. — ExenatideEzra (talk) 09:35, 18 March 2026 (UTC)
Added, with the lixisenatide trial alongside it so the point does not rest on one study. Also cross-referenced from GLP-1 receptor agonist, where the same caution appears. — SelectTrialSam (talk) 12:50, 18 March 2026 (UTC)
Good — having it in both places is right, since readers will arrive at either. ✓ Done — ExenatideEzra (talk) 08:20, 19 March 2026 (UTC)
Trp-cage descriptionDone
The C-terminal extension is described as a tryptophan cage. Worth a word on why that matters for anyone synthesising the peptide — the motif makes the crude product prone to misfolded conformers. — MolarMassMaeve (talk) 11:05, 16 January 2026 (UTC)
That is a synthesis point rather than a pharmacology point and I would put it at Solid-phase peptide synthesis instead. Added there; leaving this article on receptor affinity. ✓ Done — SPPS_Sorrel (talk) 14:40, 16 January 2026 (UTC)
Microsphere nodules
The injection-site nodule with the extended-release product is common enough to deserve a frequency figure rather than "a substantial minority". — SiteReactionSuz (talk) 10:22, 26 April 2026 (UTC)
Published rates vary widely with how the nodule was ascertained, from routine examination to spontaneous report. I would rather leave it qualitative than pick one figure. — ClinicCorrespondent (talk) 13:15, 26 April 2026 (UTC)